我们可以从死亡率数据的功能聚类中学到什么?HMD数据的应用
What can we learn from functional clustering of mortality data? An application to HMD data
摘要:
在大多数情况下,对死亡率的分析考虑到汇总指标(例如,G. $e_0$或$e^{\dagger}_0$),其关注特定的死亡率组成部分或将所有组成部分特定的信息集中在一个测量中。当我们有兴趣分析死亡率模式的全球演变而不忽视具体组成部分的演变时,这可能是一个限制。该文件分析了发达国家之间死亡率下降的模式是否不同,确定了所有死亡率组成部分所起的作用。我们使用功能数据分析(FDA)方法实现聚类分析,这使我们能够考虑特定年龄的死亡率,而不是总结措施,因为它分析曲线而不是标量数据。结合功能主成分分析(PCA)方法,它可以确定曲线的哪一部分(死亡率成分)负责将一个国家分配到特定的聚类。FDA聚类应用于1960- 2010年人类死亡率数据库的32个国家。研究结果表明,发达国家的死亡率变化具有相同的模式(但时间不同):(1)婴儿死亡率下降,(2)过早死亡率上升,(3)死亡转移和压缩。一些国家正在遵循这一计划,并正在弥补与前体的差距,另一些国家则没有显示出恢复的迹象。东欧国家仍处于第(2)阶段,尚不清楚它们是否以及何时将进入第(3)阶段。所有的国家差异都与各国经历分组所确定的阶段的不同时间有关。因此,基于FDA的聚类分析可以全面了解所考虑国家的死亡率下降模式。
英文摘要:
In most cases, mortality is analysed considering summary indicators (e.~g. $e_0$ or $e^{\dagger}_0$) that either focus on a specific mortality component or pool all component-specific information in one measure. This can be a limitation, when we are interested to analyse the global evolution of mortality patterns without loosing sight of specific components evolution. The paper analyses whether there are different patterns of mortality decline among developed countries, identifying the role played by all the mortality components. We implement a cluster analysis using a Functional Data Analysis (FDA) approach, which allows us to consider age-specific mortality rather than summary measures as it analyses curves rather than scalar data. Combined with a Functional Principal Component Analysis (PCA) method it can identify what part of the curves (mortality components) is responsible for assigning one country to a specific cluster. FDA clustering is applied to 32 countries of Human Mortality Database and years 1960--2010. The results show that the evolutions of developed countries follow the same pattern (with different timing): (1) a reduction of infant mortality, (2) an increase of premature mortality, (3) a shift and compression of deaths. Some countries are following this scheme and recovering the gap with precursors, others do not show signs of recovery. Eastern Europe countries are still at stage (2) and it is not clear if and when they will enter into phase (3). All the country differences relates the different timing with which countries undergo the stages identified by clusters. The cluster analysis based on FDA allows therefore a comprehensive understanding of the patterns of mortality decline for considered countries.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。